Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3506408 | 0.91 | PDE10A (0.67) | PDE10ACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2750052 | 0.84 | PDE10A (0.67) | PDE10ACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL519629 | 0.83 | PDE10A (0.60) | PDE10ACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3509199 | 0.82 | PDE10A (0.67) | PDE10ACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3504304 | 0.82 | PDE10A (0.65) | PDE10ACYP2C9ALDH1A1HTT | |
| SCHEMBL3504700 | 0.81 | PDE10A (0.66) | PDE10ACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL27834833 | 0.81 | PDE10A (0.57) | PDE10ACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3506625 | 0.81 | PDE10A (0.65) | PDE10ACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2504184 | 0.81 | PDE10A (0.60) | PDE10ACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3505539 | 0.81 | PDE10A (0.62) | PDE10ACYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187455-B2 | Substituted pyridazines as PDE10A inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2015-11-17 | — | — | US | claimed |
| EP-2398795-B1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-10-15 | — | — | EP | claimed |
| EP-2398795-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | claimed |
| WO-2010094762-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | claimed |
| US-20100216793-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-26 | — | — | US | claimed |
| US-9187455-B2 | Substituted pyridazines as PDE10A inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187455-B2 | Substituted pyridazines as PDE10A inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187455-B2 | Substituted pyridazines as PDE10A inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2398795-B1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-10-15 | — | — | EP | disclosed |
| EP-2398795-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| US-20100216793-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216793-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216793-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-26 | — | — | US | disclosed |
| WO-2010094762-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216793-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | PDE3A, PDE10A, PDE5A | PDE10A 2/4885CYP1A2 59/4885CYP3A4 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.